Companies / Telix Pharmaceuticals Ltd

Telix Pharmaceuticals Ltd

Nasdaq: TLXForeign · IFRSCIK 2007191NORTH MELBOURNE

Financials · FY2025

Revenue$803.79M
Net income$-7.13M
Total debt—
Cash$141.87M
Diluted EPS$-0.02
Shares outstanding338.8M

Ownership

338.8M shares outstanding
0.53%Institutions
Ownership
Institutions0.53%1,785,034
Public float99.47%336,992,015

% of common shares outstanding (single-class filing figure). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 6

View all →
Insider% of sharesShares
Behrenbruch ChristianCEOMD & Group CEO · Director
——
Gill David NDirector
——
Jellison William RDirector
——
McDonald Marie ElizabethDirector
——
Nelson Mark AlexanderDirector
——
Skinner Jann ElizabethDirector
——

Institutional holders 42

View all →
HolderValue% of shares
Portolan Capital Management, LLC$5.18M0.16%
Lazard Asset Management LLC$2.77M0.09%
Portland Investment Counsel Inc.$2.55M0.08%
Quadrature Capital Ltd$1.18M0.03%
Fmr LLC$925.5K0.04%
JPMorgan Chase & Co$557.0K0.02%
Mariner, LLC$415.3K0.01%
Marshall Wace, LLP$349.5K0.01%
Private Advisor Group, LLC$347.1K0.01%
Jane Street Group, LLC$299.9K0.01%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
No activity matches these filters.

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
TLXADREquity87961M105BBG01N69K900